Background Approximately one‐third of individuals with interstitial lung disease (ILD) have
associated connective tissue disease (CTD). The connective tissue disorders most …

This review aims to establish the impact of oxygen therapy on dyspnoea, health-related
quality of life (HRQoL), exercise capacity and mortality in interstitial lung disease (ILD). We …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Challenges for the effective management of interstitial lung diseases (ILDs) include
difficulties with the early detection of disease, accurate prognostication with baseline data …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7· 7%. We aimed to assess the …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Background Uncertainty exists regarding the clinical relevance of exercise training across
the range of interstitial lung diseases (ILDs). Objective To establish the impact of exercise …

Background The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor,
in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo …

The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease,
is estimated at 1.25–63 out of 100 000, making large population studies difficult. Recently …